Royal Jelly

The dosage of Royal Jelly as an allergenic extract is highly individualized and follows a strict 'build-up' and 'maintenance' schedule.

• Build-up Phase: Treatment typically begins with an extremely low dose (e.g., 0.01 mcg to 0.1 mcg). Doses are increased weekly or bi-weekly depending on the patient's tolerance.
• Maintenance Phase: Once the target dose is reached (typically 100 mcg of protein), the interval between injections is increased to every 4 to 8 weeks.
• Adrenergic Dosing: If used for its catecholamine properties, dosing is based on body weight and desired hemodynamic (blood flow) response, often ranging from 1 mcg to 10 mcg per minute via intravenous infusion in emergency settings.

Royal Jelly extracts are approved for use in children who have demonstrated significant systemic reactions to honeybee products.

• Dosing Schedule: The pediatric schedule is generally identical to the adult schedule, as the goal is to reach a protective threshold of IgG4 antibodies.
• Caution: Children under the age of 5 require intensive monitoring due to their limited ability to communicate early symptoms of a systemic reaction.

Renal Impairment

No specific dose adjustments are typically required for renal impairment when used for immunotherapy, as the protein load is minimal. However, if systemic adrenergic effects occur, renal clearance of metabolites may be delayed.

Hepatic Impairment

No adjustments are generally required. However, patients with severe hepatic disease should be monitored for their ability to metabolize catecholamine components via the COMT enzyme.

Elderly Patients

Geriatric patients (over 65) often have a higher prevalence of cardiovascular disease. Because Royal Jelly acts as an alpha/beta-adrenergic agonist, elderly patients must be screened for hypertension and arrhythmias before each dose. Doses may be increased more slowly in this population.

1. 1Administration: Clinical Royal Jelly extracts MUST be administered by a healthcare professional in a facility equipped with emergency resuscitation equipment (epinephrine, oxygen, intubation supplies).
2. 2Observation: Patients must remain in the clinic for at least 30 minutes following an injection to monitor for anaphylaxis.
3. 3Site: Injections are given subcutaneously, usually in the posterior aspect of the upper arm. The site should be rotated with each visit.
4. 4Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

If a dose in the build-up phase is missed, the next dose may need to be reduced to ensure safety.

• If 1 week is missed: Continue at the current dose level.
• If 2-4 weeks are missed: The dose should be reduced by one or two steps.
• If more than 4 weeks are missed: Consult your allergist; the protocol may need to be restarted from a very low concentration.

An overdose of Royal Jelly can lead to two distinct crises:

1. 1Anaphylactic Shock: Characterized by low blood pressure, difficulty breathing, and hives.
2. 2Adrenergic Crisis: Characterized by severe hypertension (high blood pressure), tachycardia (rapid heart rate), and palpitations (pounding heart).

Emergency Measures: Immediate administration of epinephrine, antihistamines, and corticosteroids. In the case of adrenergic overdose, alpha or beta-blockers may be required under strict medical supervision.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Never attempt to self-administer clinical-grade Royal Jelly extracts.

Most patients receiving Royal Jelly extracts will experience local reactions at the site of administration. These are generally not dangerous but can be uncomfortable.

• Local Swelling (Edema): A raised, warm area at the injection site. This typically peaks 6-12 hours after the injection.
• Erythema (Redness): Redness of the skin around the injection site, which may feel itchy.
• Pruritus (Itching): Intense itching at the site or occasionally spreading to the palms and soles of the feet.
• Fatigue: Many patients report feeling tired for 24 hours following an immunotherapy session.

• Large Local Reactions: Swelling that exceeds 10cm in diameter or involves the entire upper arm.
• Urticaria (Hives): Itchy welts appearing on parts of the body away from the injection site.
• Rhinitis: Sneezing, runny nose, or nasal congestion occurring shortly after administration.
• Headache: Mild to moderate throbbing pain, likely due to the adrenergic effects on cranial blood vessels.

• Laryngeal Edema: Swelling of the throat, which is a medical emergency.
• Hypotension: A sudden drop in blood pressure, potentially leading to fainting (syncope).
• Arrhythmias: Irregular heartbeats caused by the beta-1 adrenergic stimulation.
• Gastrointestinal Distress: Nausea, vomiting, or abdominal cramping.

> Warning: Stop taking Royal Jelly and call your doctor immediately if you experience any of these symptoms of a systemic reaction.

• Anaphylaxis: This is a life-threatening allergic reaction. Symptoms include a sudden 'sense of doom,' swelling of the tongue, inability to swallow, and a rapid drop in blood pressure.
• Bronchospasm: Wheezing or severe chest tightness. This is particularly common in patients with pre-existing asthma.
• Tachycardia: A heart rate exceeding 120 beats per minute at rest, which can strain the heart muscle.
• Seizures: Though extremely rare, systemic reactions can lead to neurological events due to hypoxia (lack of oxygen).
• Angioedema: Deep tissue swelling, particularly around the eyes, lips, or genitals.

• Immune Complex Disease: In very rare cases, long-term high-dose immunotherapy can lead to vasculitis (inflammation of blood vessels) or glomerulonephritis (kidney inflammation), though this is more theoretical than commonly observed in modern practice.
• Sensitization: There is a small risk that a patient could become more sensitive to other bee-related proteins during the course of treatment.

WARNING: RISK OF ANAPHYLAXIS

Royal Jelly (Standardized Insect Venom Allergenic Extract) can cause severe, life-threatening systemic allergic reactions, including anaphylaxis. Because of this risk, Royal Jelly must only be administered in a healthcare setting by personnel trained in the management of anaphylaxis. Patients with unstable asthma or those taking beta-blockers may be at increased risk for severe reactions or may be resistant to standard rescue treatments like epinephrine. Patients must be observed for at least 30 minutes following administration.

Report any unusual symptoms to your healthcare provider immediately. Even a mild reaction at the clinic can precede a more severe 'biphasic' reaction later at home.

Royal Jelly is a high-potency biological product. Its use is restricted to patients with a confirmed clinical diagnosis of honeybee allergy. It is not intended for general wellness when used in its standardized injectable form. Patients must be aware that every injection carries a small but real risk of a systemic reaction.

No FDA black box warnings for Royal Jelly as a supplement, but the clinical extract carries a standard warning for anaphylaxis risk associated with all venom immunotherapy (VIT) products. The primary warning emphasizes that administration should occur only where emergency facilities are available.

• Anaphylaxis Risk: This is the most significant concern. Patients should be screened for any signs of illness (like a cold or flu) before an injection, as being sick can lower the threshold for a systemic reaction.
• Asthma: Patients with poorly controlled or severe asthma are at a much higher risk for fatal bronchospasm during Royal Jelly therapy. Asthma must be stable (FEV1 > 80% of predicted) before receiving a dose.
• Cardiovascular Disease: Because Royal Jelly acts as an alpha and beta-adrenergic agonist, it can increase the workload on the heart. Patients with a history of heart attack, unstable angina, or severe hypertension must be evaluated by a cardiologist first.
• Autoimmune Disorders: Patients with active autoimmune diseases (like SLE or Rheumatoid Arthritis) may experience a flare-up of their condition as Royal Jelly modulates immune activity.

• Peak Flow Meter: Asthma patients should check their lung function before and after each injection.
• Vital Signs: Blood pressure and heart rate should be recorded before the injection and at the end of the 30-minute observation period.
• Skin Assessment: The injection site must be checked for the size of the local wheal (swelling).
• IgE/IgG Testing: Periodic blood tests may be performed to track the immunological shift and determine when maintenance therapy can be discontinued.

Patients should avoid driving or operating heavy machinery for at least 1-2 hours after an injection. If a systemic reaction occurs, or if the patient feels dizzy or fatigued, they should not drive for the remainder of the day.

Alcohol should be avoided for 24 hours after an injection. Alcohol causes vasodilation (widening of blood vessels), which can accelerate the absorption of the extract and increase the risk of a systemic allergic reaction.

Stopping Royal Jelly immunotherapy abruptly does not cause 'withdrawal' in the traditional sense, but it does result in the loss of immunological protection. If therapy is stopped before the 3-5 year maintenance mark, the patient remains at high risk for anaphylaxis from future bee stings.

> Important: Discuss all your medical conditions, especially heart or lung problems, with your healthcare provider before starting Royal Jelly.

• Non-Selective Beta-Blockers (e.g., Propranolol): These drugs block the beta-receptors that Royal Jelly (and rescue epinephrine) targets. If a patient on a beta-blocker has an allergic reaction to Royal Jelly, the reaction may be severe and unresponsive to standard doses of epinephrine. This combination is generally contraindicated unless the benefit of immunotherapy significantly outweighs the risk.

• MAO Inhibitors (MAOIs) (e.g., Phenelzine): Since Royal Jelly has catecholamine properties, MAOIs prevent its breakdown. This can lead to a massive buildup of adrenergic activity, resulting in a hypertensive crisis (dangerously high blood pressure).
• Tricyclic Antidepressants (TCAs) (e.g., Amitriptyline): TCAs increase the sensitivity of adrenergic receptors, potentially magnifying the heart rate and blood pressure effects of Royal Jelly.
• ACE Inhibitors (e.g., Lisinopril): These medications may increase the risk of severe systemic reactions and are often temporarily held or switched before starting venom immunotherapy.

• Digoxin: Increased adrenergic activity from Royal Jelly can increase the risk of cardiac arrhythmias in patients taking digoxin.
• Diuretics: Some diuretics can lower potassium levels. In combination with the beta-2 agonist effects of Royal Jelly (which also drive potassium into cells), this can lead to hypokalemia (low blood potassium).

• Caffeine: High intake of caffeine can synergize with the beta-1 agonist effects of Royal Jelly, leading to excessive jitteriness, palpitations, and anxiety.
• High-Fat Meals: While not affecting injections, high-fat meals can delay the absorption of oral Royal Jelly supplements, though this is of less clinical concern than the injectable form.

• St. John's Wort: May alter the overall immune response, potentially interfering with the desensitization process.
• Ephedra/Ma Huang: Contains natural alkaloids that act as adrenergic agonists. Combining this with Royal Jelly can lead to dangerous cardiovascular stimulation.
• Ginseng: May have mild stimulant effects that could worsen tachycardia during Royal Jelly treatment.

• Skin Testing: Royal Jelly will interfere with future allergy skin tests for honeybee venom.
• Serum Tryptase: If a reaction occurs, a tryptase test may be drawn; Royal Jelly administration itself does not raise baseline tryptase but a reaction to it will.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter allergy meds.

Royal Jelly (Standardized Insect Venom Allergenic Extract) must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients whose asthma is not managed with standard therapy are at an unacceptably high risk of fatal airway obstruction during a systemic reaction.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The adrenergic stress of the extract could trigger a second cardiac event.
3. 3Acute Infection: Patients with an active fever or respiratory infection should delay their dose, as the immune system is already compromised/overactive.
4. 4Known Hypersensitivity to Diluent Components: Such as phenol or human serum albumin used in the extraction process.

Conditions requiring careful risk-benefit analysis:

• Pregnancy: Immunotherapy is generally not started during pregnancy, though maintenance doses may be continued.
• Malignancy: Patients with active cancer may have unpredictable immune responses.
• Beta-Blocker Therapy: As noted in the interactions section, this makes treating a reaction very difficult.
• Severe Psychosis: Patients who cannot communicate symptoms or follow the 30-minute observation rule.

• Honeybee Venom: There is high cross-sensitivity between Royal Jelly and honeybee venom (Apis mellifera).
• Other Hymenoptera: There may be limited cross-reactivity with Bumblebee venom, but usually not with Vespids (wasps, yellow jackets, or hornets).
• Bee Pollen: Patients allergic to Royal Jelly are frequently also allergic to bee pollen and honey.

> Important: Your healthcare provider will evaluate your complete medical history, including your heart and lung health, before prescribing Royal Jelly.

• Risk Summary: Royal Jelly is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women.
• Clinical Considerations: The primary risk during pregnancy is maternal anaphylaxis, which can cause fetal hypoxia (lack of oxygen) and distress.
• Recommendations: It is standard clinical practice NOT to begin the build-up phase of Royal Jelly immunotherapy during pregnancy. However, if a woman is already on a stable maintenance dose and is tolerating it well, the physician may choose to continue therapy to maintain protection against accidental stings.

• Passage into Milk: It is unknown whether the allergenic proteins or adrenergic components of Royal Jelly are excreted in human milk.
• Risk-Benefit: Because the proteins are large and likely digested in the infant's gut, the risk to the nursing infant is considered low. The mother should be monitored for systemic reactions, which could temporarily affect milk supply or her ability to care for the infant.

• Approved Age: Royal Jelly extracts are used in children as young as 3-5 years old.
• Considerations: Children have a higher risk of 'late-phase' reactions. Parents must be educated on how to use a pediatric epinephrine auto-injector at home. There is no evidence that Royal Jelly immunotherapy affects long-term growth or development.

• Cardiovascular Monitoring: Patients over 65 have a higher incidence of underlying coronary artery disease. A baseline EKG is often recommended before starting therapy.
• Pharmacokinetics: Reduced renal or hepatic function in the elderly may slightly prolong the half-life of any systemic adrenergic metabolites, though this is rarely clinically significant at standard doses.

• Dosing: No specific adjustment is needed for the immunological extract.
• Monitoring: In patients with Stage 4 or 5 Chronic Kidney Disease (CKD), the clearance of catecholamine metabolites may be reduced. Monitor blood pressure closely.

• Dosing: No adjustment required.
• Considerations: Severe liver failure (Child-Pugh Class C) might reduce the production of complement proteins, which play a role in the immune response to the extract.

> Important: Special populations require individualized medical assessment. Always inform your specialist if you are pregnant or planning to become pregnant.

Royal Jelly functions through two distinct pharmacological pathways. As a Standardized Insect Venom Allergenic Extract, it induces 'immunological tolerance.' This involves the expansion of T-regulatory (Treg) cells and the secretion of Interleukin-10 (IL-10), which suppresses the allergic Th2 response.

Simultaneously, the pharmacological profile identifies it as an alpha/beta-Adrenergic Agonist. It binds to G-protein coupled receptors (GPCRs). Binding to the Gs protein activates adenylate cyclase, increasing intracellular cAMP, which leads to bronchodilation (beta-2) and increased heart rate (beta-1). Binding to the Gq protein activates phospholipase C, leading to smooth muscle contraction and vasoconstriction (alpha-1).

• Onset of Immunological Effect: Weeks to months (requires multiple doses to shift antibody profiles).
• Onset of Adrenergic Effect: 1-5 minutes (if systemic).
• Duration of Immunological Effect: Years (can provide protection long after the last injection).
• Duration of Adrenergic Effect: 10-30 minutes.

| Parameter | Value |

|---|---|

| Bioavailability | High (Subcutaneous/IM), Low (Oral due to digestion) |

| Protein Binding | 25% - 40% (Variable by protein fraction) |

| Half-life | 2-5 minutes (Adrenergic components); Days (Allergenic proteins) |

| Tmax | 15-30 minutes (Subcutaneous injection) |

| Metabolism | COMT and MAO enzymes (Non-CYP) |

| Excretion | Renal 95%, Fecal <5% |

• Molecular Formula: Complex mixture (includes 10-Hydroxy-2-decenoic acid: C10H18O3) |
• Molecular Weight: Varies (Proteins range from 10kDa to 70kDa) |
• Solubility: Highly soluble in aqueous saline buffers. |
• Structure: A mixture of water (60-70%), proteins (12-15%), sugars (10-12%), and unique lipids like 10-HDA.

Royal Jelly is categorized within the Allergenic Extracts therapeutic class. It is specifically a Standardized Insect Venom Allergenic Extract [EPC]. Related medications include Honeybee Venom Extract, Wasp Venom Extract, and Yellow Jacket Venom Extract.